<?xml version="1.0" encoding="UTF-8"?>
<p>Besides a higher titer, the epitopes targeted by cross-neutralizing antibodies that develop post-secondary infection appear also to be different compared to post-primary infection, as mentioned above [
 <xref rid="B9-vaccines-08-00174" ref-type="bibr">9</xref>,
 <xref rid="B10-vaccines-08-00174" ref-type="bibr">10</xref>,
 <xref rid="B13-vaccines-08-00174" ref-type="bibr">13</xref>,
 <xref rid="B14-vaccines-08-00174" ref-type="bibr">14</xref>,
 <xref rid="B15-vaccines-08-00174" ref-type="bibr">15</xref>,
 <xref rid="B16-vaccines-08-00174" ref-type="bibr">16</xref>], and this could also impact differently vaccine take. Further studies are needed to address this question. 
</p>
